Abstract
Biomarkers linked to patient outcomes (safety and efficacy) have an increasingly important role in drug development. Consequently, validation and qualification of such biomarkers are essential, often requiring large data sets from well-controlled randomized clinical trials. In the December 2009 issue of Clinical Pharmacology Therapeutics, investigators utilizing data from four pharmaceutical companies and working under the auspices of the Biomarkers Consortium described the utility of adiponectin as an early predictor of glycemic control in diabetic patients taking peroxisome proliferator-activated receptor (PPAR) agonists. This work illustrates the advantages of large public-private partnerships for biomarker qualification.
Original language | English |
---|---|
Pages (from-to) | 21-23 |
Number of pages | 3 |
Journal | Clinical pharmacology and therapeutics |
Volume | 87 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2010 |